Business Wire

Fedrigoni and Palantir Partner to Accelerate Operational Transformation with AI

10.6.2025 12:59:00 CEST | Business Wire | Press Release

Share

Palantir Technologies Inc. (NASDAQ: PLTR) today announced a multi-year partnership with Fedrigoni, a global reference manufacturer of specialty papers for packaging and other creative applications, self-adhesive labels, graphic supports for visual communication, and RFID. This strategic alliance aims to accelerate Fedrigoni's digital transformation by leveraging advanced AI capabilities and Palantir's innovative solutions. Initially focused on stock optimization and demand forecasting, the partnership is now expanding to support Fedrigoni's comprehensive digital transformation objectives.

The collaboration between Fedrigoni and Palantir represents a pivotal step in enhancing operational efficiency and driving innovation across Fedrigoni's global operations. By utilizing Palantir's cutting-edge AI technology, Fedrigoni seeks to improve its responsiveness to market dynamics and enhance its ability to anticipate and meet customer demands. Fedrigoni is advised on this project by Avatar Investments, a preferred Partner of Palantir in Italy.

"We are delighted to deepen our partnership with Palantir as we embark on this transformative journey," stated Marco Nespolo, CEO of Fedrigoni. "Our collaboration with Palantir will enable us to harness the power of AI to be increasingly agile and competitive in a rapidly evolving market. This partnership is a critical component of our strategy to lead the industry in operational excellence and customer service." Gionata Berna, CIO of Fedrigoni, also emphasized the strategic importance of the partnership: "Integrating Palantir's AI solutions into our operations signifies a major advancement in our digital innovation strategy. The ability to accurately forecast demand and optimize stock levels is just the beginning. We are committed to building a data-driven organization that can swiftly adapt to changes and capitalize on new opportunities."

Palantir's Managing Director for Palantir France and EMEA Executive, François Bohuon, expressed enthusiasm for the partnership: "We are excited to collaborate with Fedrigoni on their digital transformation journey. This partnership highlights the transformative potential of AI in traditional industries, and we are honored to support Fedrigoni in achieving their strategic vision. Our technology will empower them to unlock new efficiencies and drive growth." Guillaume Soule, EMEA Manufacturing AI Lead at Palantir, added, "Fedrigoni's forward-thinking approach to digital transformation aligns perfectly with our mission to empower organizations through data-driven insights. By leveraging AI, we are poised to deliver impactful results that will enable Fedrigoni to enhance its operational capabilities and achieve sustained success."

This partnership underscores the growing importance of digital transformation in traditional manufacturing sectors and highlights the role of AI in driving innovation and efficiency. Both companies are committed to a collaborative approach that will deliver breakthrough solutions and create long-term value.

About Palantir Technologies Inc.

Foundational software of tomorrow. Delivered today. Additional information is available at https://www.palantir.com.

About Fedrigoni

Founded in 1888 in Verona, Fedrigoni is today the global leader in specialty papers for luxury packaging and premium labels for wines, the third player in the self-adhesive materials market and RFID inlay production, and the second in art and drawing papers with Fabriano brand. With nearly 6,000 people in 28 countries and 74 plants including production sites, cutting and distribution centers, the Group sells and distributes over 25,000 products in 132 countries. For more information: www.fedrigoni.com

About Avatar Investments

Founded in 2024 by Ludovico Fassati and Riccardo Basile, Avatar is helping companies achieve their full potential using the latest AI technologies. Avatar has a unique approach melting consulting with investing. For more information: www.avatar-investments.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir’s expectations regarding the amount and the terms of the contract and the expected benefits of our software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond Palantir's control. These risks and uncertainties include the ability to meet the unique needs of customers; the failure of Palantir's platforms to satisfy customers or perform as desired; the frequency or severity of any software and implementation errors; Palantir's platforms’ reliability; and customers' ability to modify or terminate the contract. Additional information regarding these and other risks and uncertainties is included in the filings Palantir makes with the Securities and Exchange Commission from time to time. Except as required by law, Palantir does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250610466164/en/

Contacts

Palantir Contact
Lisa Gordon
media@palantir.com

Fedrigoni Contact
Stefania Vicentini
+39 335 5613180, sv@dicomunicazione.it

Avatar Investments Contact
info@avatar-investments.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye